Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $13
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
Read original at benzingaStocks · News reference
Orthofix Medical Q2 Adj. EPS $0.07 Beats $(0.41) Estimate, Sales $210.933M Beat $209.277M Estimate
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.41) by 117.07 percent. This is a 46.15 percent decrease over earnings of $0.13 per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 11:01 AM
- Checked
- Aug 5, 2026, 11:01 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Orthofix shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Read original at benzinga8-K filing — Orthofix Medical Inc. (OFIX)
Filed: 2026-08-05 AccNo: 0001193125-26-333817 Size: 30 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarOrthofix Medical Raises FY2026 Sales Guidance from $838.000M-$848.000M to $845.000M-$855.000M vs $843.311M Est
Orthofix Medical (NASDAQ:OFIX) raises FY2026 sales outlook from $838.000 million-$848.000 million to $845.000 million-$855.000 million vs $843.311 million estimate.
Read original at benzinga